|

Ublituximab Clinical Trials

6 actively recruiting trials across 5 locations

▲ +1 trial since May 2026

Also known as: BRIUMVI, Briumvi, TG-1101

Pipeline

Early 1: 1Phase 3: 1Phase 4: 2

Top Sponsors

  • University of Maryland, Baltimore1
  • TG Therapeutics, Inc.1
  • Northwestern University1
  • Neurology Center of New England P.C.1
  • Johns Hopkins University1

Indications

  • Multiple Sclerosis6
  • Multiple Sclerosis (MS) - Relapsing-remitting3
  • Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis1
  • Relapsing Multiple Sclerosis1

Baltimore, Maryland2 trials

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

University of Maryland, Baltimore

N/A
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

Johns Hopkins University

Phase 4

Birmingham, Alabama1 trial

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

TG Therapeutics Investigational Trial Site

Phase 3

Atlanta, Georgia1 trial

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Georgia State University

Early 1

Chicago, Illinois1 trial

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Northwestern Memorial Hospital

Phase 4

Foxborough, Massachusetts1 trial

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Neurology Center of New England P.C.

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.